The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY
Main Article Content
Keywords
Abstract
The objective of this two-part review is to present a current and comprehensive understanding of the diagnosis and management of plasmablastic lymphoma. The first part, which was published previously, focused on the study of epidemiology, etiology, clinopathological characteristics, differential diagnosis, prognostic variables, and the impact of plasmablastic lymphoma on specific populations. This second part addresses the difficult topic of the treatment of plasmablastic lymphoma, specifically examining both the conventional, consolidated approach and the novel therapeutic strategy.
Downloads
Download data is not yet available.
Abstract 481
PDF Downloads 520
HTML Downloads 105
References
1. Stein H. & Dallenbach F. in Neoplastic Hematopathology (ed.Knowles, D.M.) 675-714 (Williams & Wilkins, Baltimore, MA, 1992).
2. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-1420. PMid:9028965
3. Bibas M. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Prognostic Factors, and Special Populations. Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024007. doi: 10.4084/MJHID.2024.007. PMID: 38223486; PMCID: PMC10786126.
4. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. PMID: 35732829; PMCID: PMC9214472.
5. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851. PMID: 35653592; PMCID: PMC9479027.
6. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 9;125(15):2323-30. doi: 10.1182/blood-2014-10-567479. Epub 2015 Jan 30. PMID: 25636338.
7. Bibas M, Castillo JJ. Current knowledge on HIVassociated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064.
8 .Castillo JJ, Furman M, Beltrán BE,et al.: Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 1;118(21):5270-7. doi: 10.1002/cncr.27551. Epub 2012 Apr 17. PMID: 22510767.
9. Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Survival analysis in treated plasmablastic
lymphoma patients: a population-based study. Am J Hematol. Nov 2020;95(11):1344-1351.
doi:10.1002/ajh.25955).
10. Alec R. Hansen , Victoria A. Vardell , Lindsey A. Fitzgerald , Epidemiologic characteristics, treatment patterns, and survival analysis of Plasmablastic Lymphoma in the US: A SEER and NCDB analysis., Clinical Lymphoma, Myeloma and Leukemia (2023), doi: https://doi.org/10.1016/j.clml.2023.12.014)
11 Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008 Oct;83(10):804-9. doi: 10.1002/ajh.21250. PMID: 18756521.
12. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293-9. doi: 10.1634/theoncologist.2009-0304. Epub 2010 Feb 18. PMID: 20167839; PMCID: PMC3227958.
13. Ibrahim IF, Shapiro GA, Naina HVK. Treatment of HIV-associated plasmablastic lymphoma: a single-center experience with 25 patients. J Clin Oncol 2014; 32(15Suppl):8583.
14 Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, Hu S, Yin CC, Miranda RN, Medeiros LJ, Khoury JD. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015 Jun 10;8:65. doi: 10.1186/s13045-015-0163-z. PMID: 26055271; PMCID: PMC4472407.
15 .Pinnix CC, Shah JJ, Chuang H, et al. Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review. Clin Lymphoma Myeloma Leuk 2016; 16:122-8.
16 .Rudresha AH, Lakshmaiah KC, Agarwal A, et al. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India. South Asian J Cancer 2017; 6:69-71.
17. Focà E, Cavaglià G, Rusconi S, et al. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Med 2018, Online ahead of print
18. Al Tabaa Y, Tchernonog E, Faurie P, et al. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in plasmablastic lymphoma. Eur J Nucl Med Mol Imaging 2018; 45:1705-9.
19. Zuze T, Painschab MS, Seguin R, et al. Plasmablastic lymphoma in Malawi. Infect Agent Cancer 2018; 13:22.
20. Rodrigues-Fernandes CI, de Souza LL, Dos Santos-Costa SF, et al. Clinicopathological analysis of oral plasmablastic lymphoma: a systematic review. J Oral Pathol Med 2018; 47:915-22.
21. Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. PMID: 37832030.
22. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. NCCN 2024;Version 1..2024- 18 January 2024
23. Robak P, Robak T. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9. PMID: 30993606; PMCID: PMC6544598.
24. Leonard JP, Kolibaba K, Reeves JA, et al. Randomized phase 2 openlabel study of R-CHOP ± bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the Pyramid trial (NCT00931918). Blood. 2015;126(23):811. 44.
25. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–953.
26. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20. PMID: 19380866; PMCID: PMC2699229.
27. Jambusaria A, Shafer D, Wu H, Al-Saleem T, Perlis C. Cutaneous plasmablastic lymphoma. J Am Acad Dermatol. 2008 Apr;58(4):676-8. doi: 10.1016/j.jaad.2007.08.009. PMID: 18342714.
28. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009 Jun;82(6):490-2. doi: 10.1111/j.1600-0609.2009.01235.x. Epub 2009 Feb 5. PMID: 19220417.
29.Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010 Dec 1;28(34):e704-8. doi: 10.1200/JCO.2010.30.0038. Epub 2010 Sep 7. PMID: 20823416.
30. Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):E43-6. doi: 10.3816/CLML.2010.n.074. PMID: 21856550.
31. Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013 Sep;31(3):164-6. doi: 10.1002/hon.2024. Epub 2012 Aug 17. PMID: 22899491.
32. Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, Safah H. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36(5):287-91. doi: 10.1159/000350325. Epub 2013 Apr 5. PMID: 23689224.
33. Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e145-50. doi: 10.1016/j.clml.2014.03.002. Epub 2014 Jun 11. PMID: 25225082.
34. Cencini E, Fabbri A, Guerrini S, Mazzei MA, Rossi V, Bocchia M. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016 Jun;96(6):650-654. doi: 10.1111/ejh.12732. Epub 2016 Jan 19. PMID: 26715026.
35.Hirosawa M, Morimoto H, Shibuya R, Shimajiri S, Tsukada J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res. 2015 Nov 4;3:28. doi: 10.1186/s40364-015-0053-0. PMID: 26543559; PMCID: PMC4634743.
36. Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352–355
37. Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, et al. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma. 2016;57(2):463–466.
38. Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, Grigoriadis G. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016 Mar;95(4):667-8. doi: 10.1007/s00277-016-2601-6. Epub 2016 Jan 23. PMID: 26801792.
39. Arora N, Gupta A, Sadeghi N. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. BMJ Case Rep. 2017 Oct 9;2017:bcr2017222063. doi: 10.1136/bcr-2017-222063. PMID: 28993364; PMCID: PMC5652596.
40. Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62(September):12–16
41. Dittus C, Grover N, Ellsworth S, Tan X, Park SI. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma. 2018 Sep;59(9):2121-2127. doi: 10.1080/10428194.2017.1416365. Epub 2018 Jan 5. PMID: 29303024.
42. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. PMID: 29527667.
43. Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, Sawayama Y, Hata T, Ohshima K, Miyazaki Y. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma. Oncol Res Treat. 2020;43(3):112-116. doi: 10.1159/000504608. Epub 2019 Dec 16. PMID: 31842017.
44. Umeanaeto O, Gamboa J, Diaz J, Hakim MN, Corral J, Philipovskiy A, Gaur S. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. Anticancer Res. 2019 Sep;39(9):5003-5007. doi: 10.21873/anticanres.13690. PMID: 31519607.
45. Cai J, Qiu L, Ma L, Zhang N, Fan FY. Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma. Front Med (Lausanne). 2021 Dec 3;8:749863. doi: 10.3389/fmed.2021.749863. PMID: 34926499; PMCID: PMC8677941.
46. Sabry W, Wu Y, Kodad SG. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach. Curr Oncol. 2022 Jul 18;29(7):5042-5053. doi: 10.3390/curroncol29070399. PMID: 35877259; PMCID: PMC9323819.
47. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 1;33(25):2803-11. doi: 10.1200/JCO.2014.59.5363. Epub 2015 Jul 20. PMID: 26195701; PMCID: PMC5320950.
48. Carras, S.; Regny, C.; Peoc’h, M.; Gervasoni, J.; Gressin, R.; Cahn, J.Y.; Molina, L. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric nonhuman immunodeficiency virus-associated plasmablastic lymphoma. Leuk. Lymphoma 2015, 56, 2986–2988. [CrossRef] [PubMed]
49. Yanamandra, U.; Sahu, K.K.; Jain, N.; Prakash, G.; Saikia, U.; Malhotra, P. Plasmablastic lymphoma: Successful management with CHOP and lenalidomide in resource constraint settings. Ann. Hematol. 2016, 95, 1715–1717.
50. Schmit J.M.; Delaune, J.; Norkin, M.; Grosbach, A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol. Res. Treat. 2017, 40, 46–48.
51. Marrero, W.D.; Cruz-Chacón, A.; Castillo, C.; Cabanillas, F. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma. Clin. Lymphoma Myeloma Leuk. 2018, 18, e275–e277.
52..Cheng, L.; Song, Q.; Liu, M.; Wang, Y.; Yi, H.; Qian, Y.; Xu, P.; Cheng, S.; Wang, C.; Wang, L.; et al. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient with Tislelizumab and Lenalidomide. Front. Immunol. 2021, 12, 702593.
53. Lee M, Martin BA, Abdulhaq H. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature. Case Rep Hematol. 2022 Jun 27;2022:8331766. doi: 10.1155/2022/8331766. PMID: 35795542; PMCID: PMC9252825.
54.Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017 Dec;52(4):243-253. doi: 10.5045/br.2017.52.4.243. Epub 2017 Dec 26. PMID: 29333400; PMCID: PMC5762734.
55.Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018 Aug 6;11:4583-4590. doi: 10.2147/OTT.S141053. PMID: 30122950; PMCID: PMC6084082.
56. Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013 Apr 20;31(12):e197-9. doi: 10.1200/JCO.2012.46.9593. Epub 2013 Mar 18. PMID: 23509308.
57. Luo B, Huang L, Gu Y, et al. Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol 2018; 11: 5547–60.
58. Culjkovic-Kraljacic B, Fernando TM, Marullo R, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood 2016; 127: 858–68.
59. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 2017; 129: 3175–83.
60.Laín S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res 1999; 253: 315–24
61.Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727–38
62.Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs 2019; 29: 15–21.
63.Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li RJ, Ma L, et al. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Oncologist. 2021;26(10):879-86.
64.Podar K, Shah J, Chari A, Richardson PG, Jagannath S. Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother. 2020;21(4):399-408
65.Yuhua F, Renjun B, Yonghua Y, Zhang T, Chen L. Selinexor in the Treatment of a Patient with Refractory Plasmablastic Lymphoma: A Case Reports. Ann Short Rep Clin Image. 2022; 3(3): 1028.
66. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004 Apr;121(4):482-8. doi: 10.1309/74R4-TB90-BUWH-27JX. PMID: 15080299.
67. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. PMID: 21187443.
68. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24. PMID: 27222480; PMCID: PMC4957162.
69.Morabito F, Damle RN, Deaglio S et al. The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol. Med. 2006; 12(11–12):342–4.
70. Patten PEM, Buggins AGS, Richards J et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008; 111(10):5173–81.
71.Konoplev S, Medeiros LJ, Bueso-Ramos CE et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am. J. Clin. Pathol. 2005;124(3):414–20.
72. Parry-Jones N, Matutes E, Morilla R et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: A study of 60 cases by FISH. Br. J. Haematol. 2007; 137(2):117–124.
73. Keyhani A, Huh YO, Jendiroba D et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk. Res. 2000; 24(2):153–9.
74.Marinov J, Koubek K, Starý J. Immunophenotypic significance of the “lymphoid” CD38 antigenin myeloid blood malignancies. Neoplasma 1993; 40(6):355–8.
75.Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer-cell leukemia revisited:large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18(4):763–70.
76.Wang L, Wang H, Li P et al. CD38 expression predicts poor prognosis and might be a potentialtherapy target in extranodal NK/T cell lymphoma, nasal type. Ann. Hematol. 2015;94(8):1381–8.
77. Hari P, Raj R V, Olteanu H. Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-CellLymphoma. N. Engl. J. Med. 2016; 375(15):1501–1502.
78. Bride KL, Vincent TL, Im S-Y et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018; 131(9):995–999.
79. Overdijk MB, Verploegen S, Bögels M et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015; 7(2):311–21.
80. Chikeka I, Grossman M, Deng C, Jacob AT, Husain S. Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. JAAD Case Rep. 2020 Feb 12;6(3):161-165. doi: 10.1016/j.jdcr.2019.11.007. PMID: 32083160; PMCID: PMC7019043.
81. Marvyin K, Tjønnfjord EB, Breland UM, Tjønnfjord GE. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. BMJ Case Rep. 2020 Sep 29;13(9):e235816. doi: 10.1136/bcr-2020-235816. PMID: 32994268; PMCID: PMC7526319.
82. Roché P, Venton G, Berda-Haddad Y, Fritz S, Ivanov V, Mercier C, Colle J, Tichadou A, Fanciullino R, Lepidi H, Costello R, Farnault L. Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?-Potential therapeutic applications. Eur J Haematol. 2021 Apr;106(4):589-592. doi: 10.1111/ejh.13584. Epub 2021 Feb 2. PMID: 33469987.
83. Ricker E, Yun Kyoung Ryu, Jennifer E. Amengual, Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma, Blood,Volume 138, Supplement 1,2021,Page 4573
84. Ramadas P, Williams M, Duggan DB. Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder. Case Rep Hematol. 2021 Sep 27;2021:4354941. doi: 10.1155/2021/4354941. PMID: 34616575; PMCID: PMC8490046.
85. Kathrotiya M, Radhakrishnan VS, Bhave SJ, Kumar J, Roychowdhury M, Arun I, Das J, Chandy M, Nair R. Relapsed plasmablastic lymphoma in a HIV-negative patient: Pushing the envelope. Clin Case Rep. 2020 Dec 20;9(2):873-877. doi: 10.1002/ccr3.3673. PMID: 33598263; PMCID: PMC7869339.
86. Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J Clin Med. 2022 Aug 22;11(16):4928. doi: 10.3390/jcm11164928. PMID: 36013165; PMCID: PMC9409851.
87. Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023 Feb 15;30(2):2322-2347. doi: 10.3390/curroncol30020179. PMID: 36826140; PMCID: PMC9954856.
88. Pinto MP, Thorneloe NS, Brown MR, Stalons ML, Stoll KE, Holmes AR, Pathan M, Gonzales PA. The devolution of a mature plasma cell dyscrasia into a fatal plasmablastic lymphoma. J Case Rep Images Oncology 2023;9(2):7–14.
89. Dornan D, Bennett F, Chen Y et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkinlymphoma. Blood 114:2721–2729
90. Deeks ED (2019) Polatuzumab vedotin: first global approval. Drugs 79:1467–1475.
91. Palanca-Wessels MCA, Czuczman M, Salles G et al (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
92. Sehn L, Herrera A, Flowers C et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155–165
93. Northend M, Wilson W, Osborne W. et al.: Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. PMID: 35020818; PMCID: PMC9092410.
94. Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017, 8, 561.
95. Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11, 3887–3895.
96. Ishida, Y. PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells 2020, 9, 1376.
97. Jalali, S.; Price-Troska, T.; Bothun, C.; Villasboas, J.; Kim, H.J.; Yang, Z.Z.; Novak, A.J.; Dong, H.; Ansell, S.M. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019, 9, 22.
98. Xu-Monette, Z.Y.; Zhou, J.; Young, K.H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 2018, 131, 68–83.
99. Garcia-Lacarte, M.; Grijalba, S.C.; Melchor, J.; Arnaiz-Leche, A.; Roa, S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers 2021, 13, 4683.
100. Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2, 261–268.
101. Xia, Y.; Medeiros, L.J.; Young, K.H. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016, 30, 189–200.
102. Bardhan, K.; Anagnostou, T.; Boussiotis, V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front.Immunol. 2016, 7, 550.
103. Azuma, T.; Yao, S.; Zhu, G.; Flies, A.S.; Flies, S.J.; Chen, L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008,111, 3635–3643.
104. Zhang, J.P.; Song, Z.; Wang, H.B.; Lang, L.; Yang, Y.Z.; Xiao, W.; Webster, D.E.; Wei, W.; Barta, S.K.; Kadin, M.E.; et al. A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening. Blood 2019, 134,171–185.
105. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.;Gettinger, S.N.; et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014,515, 563–567.
106. Xie, W.; Medeiros, L.J.; Li, S.; Yin, C.C.; Khoury, J.D.; Xu, J. PD-1/PD-L1 Pathway and Its Blockade in Patients with ClassicHodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr. Hematol. Malig. Rep. 2020, 15, 372–381.
107. Ansell, S.M. PD-1 Blockade in Classic Hodgkin Lymphoma. JCO Oncol. Pract. 2021, 17, 72–73. [CrossRef]
108. Chen, B.J.; Chapuy, B.; Ouyang, J.; Sun, H.H.; Roemer, M.G.; Xu, M.L.; Yu, H.; Fletcher, C.D.; Freeman, G.J.; Shipp, M.A.; et al.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res.2013, 19, 3462–3473.
109.Kiyasu, J.; Miyoshi, H.; Hirata, A.; Arakawa, F.; Ichikawa, A.; Niino, D.; Sugita, Y.; Yufu, Y.; Choi, I.; Abe, Y.; et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood2015, 126, 2193–2201
110. Granai M, Mundo L, Akarca AU, Siciliano MC, Rizvi H, Mancini V, Onyango N, Nyagol J, Abinya NO, Maha I, Margielewska S, Wi W, Bibas M, Piccaluga PP, Quintanilla-Martinez L, Fend F, Lazzi S, Leoncini L, Marafioti T. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infect Agent Cancer. 2020 May 6;15:28. doi: 10.1186/s13027-020-00292-w. Erratum in: Infect Agent Cancer. 2020 Jun 10;15:39. PMID: 32391073; PMCID: PMC7201729.
111. Xing, W.; Dresser, K.; Zhang, R.; Evens, A.M.; Yu, H.; Woda, B.A.; Chen, B.J. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications. Oncotarget 2016, 7, 59976–59986.
112. Laurent C, Fabiani B, Do C, Tchernonog E, Cartron G, Gravelle P, Amara N, Malot S, Palisoc MM, Copie-Bergman C, Glehen AT, Copin MC, Brousset P, Pittaluga S, Jaffe ES, Coppo P. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016 Aug;101(8):976-84. doi: 10.3324/haematol.2016.141978. Epub 2016 May 12. PMID: 27175027; PMCID: PMC4967577.
113. Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C. EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology. 2018 Jul 30;7(10):e1486950. doi: 10.1080/2162402X.2018.1486950. PMID: 30288350; PMCID: PMC6169584.
114. Damlaj M., Alzayed M., Alahmari B., Alhejazi A., Alaskar A., Alzahrani M. Therapeutic potential of checkpoint inhibitors in refractory plasmablastic lymphoma. Clinical Lymphoma Myeloma and Leukemia . 2019;19(10):e559–e563. doi: 10.1016/j.clml.2019.06.008. [PubMed] [CrossRef] [Google Scholar]
115.Cheng L., Song Q., Liu M., et al. Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide. Frontiers in Immunology . 2021;12 doi: 10.3389/fimmu.2021.702593.702593
116. Castillo JJ, Lamacchia J, Silver J, Flynn CA, Sarosiek S. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 Oct 1;96(10):E390-E392. doi: 10.1002/ajh.26291. Epub 2021 Aug 2. PMID: 34260089.
117. Schuster, S.J. , Svoboda, J. , Chong, E.A. , Nasta, S.D. , Mato, A.R. , Anak, O. , Brogdon, J.L. , Pruteanu‐Malinici, I. , Bhoj, V. , Landsburg, D. , Wasik, M. , Levine, B.L. , Lacey, S.F. , Melenhorst, J.J. , Porter, D.L. & June, C.H. (2017) Chimeric antigen receptor T cells in refractory B‐cell lymphomas. The New England Journal of Medicine, 377, 2545–2554.
118. Abramson, J.S. & Chen, Y.B. (2017) More on anti‐CD19 CAR T cells in CNS diffuse large‐B‐cell lymphoma. The New England Journal of Medicine, 377, 2102.
119. Testa U, Leone G, Pelosi E, Castelli G, Hohaus S. CAR-T Cell Therapy in Large B Cell Lymphoma. Mediterr J Hematol Infect Dis. 2023 Nov 1;15(1):e2023066. doi: 10.4084/MJHID.2023.066. PMID: 38028399; PMCID: PMC10631715.
120 .Parker C, Liu FF, Deger KA, Franco-Villalobos C, Proskorovsky I, Keating SJ, Sorensen S. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Adv Ther. 2023 May;40(5):2355-2374. doi: 10.1007/s12325-023-02444-x. Epub 2023 Mar 22. PMID: 36947328; PMCID: PMC10129927.
121 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. PMID: 34478487; PMCID: PMC8945634.
122.Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwartz E, Jakovach M, Martinez-Prieto M, Agarwal A, Degtyarev E, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2022; 6: 2536-2542.
123.Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022, 386(7): 629-639.
124. Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Med 2022; 28: 2145-
125. Raychaudhuri R, Qualtieri J, Garfall AL. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. Am J Hematol. 2020 Jan;95(1):E28-E30. doi: 10.1002/ajh.25682. Epub 2019 Nov 25. PMID: 31725923.
126. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014 Dec;20(12):1877-84. https://doi.org/10.1016/j.bbmt.2014.06.009 PMid:24946718
127. Cattaneo C, Finel H, McQuaker G, Vandenberghe E, Rossi G, Dreger P. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant. 2015 Jun;21(6):1146-7.
128. Balsalobre P, Diez-Martin J, Re A, et al. Autologous stem cell transplantation in patients with HIV related lymphoma. J Clin Oncol. 2009; 27:2192-2198
129. Re A, Michieli M, Allione B, et al. Early consolidation with high dose therapy and autologous stem cell transplantation in HIV-associated Non Hodgkin Lymphoma at high risk (aa-IPI 2-3), an interim report of a multicenter phase II trial. Blood. 2012;120. Abstract 731.
130. Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among HIVpositive patients: results of a single centre’s experience. Leuk Lymphoma. 2014 Apr 9 [Epub ahead of print].
131. Broccoli A, Nanni L, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer. 2018 Jun 8;18(1):645. doi: 10.1186/s12885-018-4561-9. PMID: 29879938; PMCID: PMC5992724.
132. M. Hamadani, S.M. Devine.Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood,114 (2009), pp. 2564-2566
133. Rong C, Sheng L, Wu A, Sun Y, Ouyang G. Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24498. doi: 10.1097/MD.0000000000024498. PMID: 33607779; PMCID: PMC7899902
134. Illidge T, Specht L, Yahalom J, et al. Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 2014;89(1):49–58
136. Ng AK, Yahalom J, Goda JS, et al. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 2018;100(3):652–69.
137. Shi Z, Das S, Okwan-Duodu D, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):569-577. doi:10.1016/j.ijrobp.2013.02.007
138. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170-4176. doi:10.1200/JCO.2009.27.3441
139. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032-3038. doi:10.1200/JCO.2004.06.088
140. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21-26. doi:10.1056/NEJM199807023390104
141. Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112-1118. doi:10.1200/JCO.2013.51.4505
142. Pfreundschuh M, Murawski N, Ziepert M, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J Clin Oncol. 2018;36(15_suppl):7574-7574. doi:10.1200/JCO.2013.51.4505
143. Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115-4122. doi:10.1200/JCO.2012.48.0467
144. Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-669. doi:10.1016/j.ijrobp.2017.12.005
145. Wright CM, Koroulakis AI, Baron JA, et al. Palliative radiotherapy for diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(10):650-658. doi:10.1016/j.clml.2021.05.007
146. Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol Rep. 2015 Apr;33(4):1615-20. doi: 10.3892/or.2015.3808. Epub 2015 Feb 17. PMID: 25695332; PMCID: PMC4358079.
147. Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fabiani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017 Apr 1;28(4):843-848. doi: 10.1093/annonc/mdw684. PMID: 28031174.
148. Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 Feb;98(2):300-308. doi: 10.1002/ajh.26784. Epub 2023 Jan 1. PMID: 36588409; PMCID: PMC10107934.
149. Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516.
150. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis—a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15(8):451-457.
151. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926.
152. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-3156.
153.Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):578-586.
154.Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br JHaematol. 2017;176(2):210-221.
155. Hu S, Song Y, Li Y, et al. Primary breast diffuse large B cell lymphoma in the rituximab era: outcomes of a multicenter retrospective study by the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society (LLC-CGOS). Paper presented at: 58th Annual Meeting of the American Society of Hematology; 3-6 December 2016; San Diego, CA.
156. McKay P, Wilson MR, Chaganti S, et al; British Society of Haematology. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2020;190(5):708-714.
157. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer.2017;75(April):195-203.
158. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.Blood. 2016;127(18):2182-2188
159.Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2014;99(7):1228-1235.
160. Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica.2020;105(7):1914-1924.
161.Eyre TA, Kirkwood AA, Wolf J, et al. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br J Haematol. 2019;187(2):185-194
162.Barta SK, Joshi J, Mounier N, et al. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol 2016;173:857-66.
163. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al.Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521–9.
164. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430–8.
165. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol. 2001;112:909–15.
166. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91:155–63.
167.Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, et al Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect. 2014;20:O672–9.
168. Gonzalez-Garcia JJ, Mahillo B, Hernandez S, Pacheco R, Diz S, Garcia P, et al. [Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients.The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. Enferm Infecc Microbiol Clin. 2005;23:340–8.
169. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS.2005;19:593–601.
170. Berenguer J, Rivero A, Jarrin I, Nunez MJ, Vivancos MJ, Crespo M, et al. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics. Open Forum Infect Dis. 2016;3:ofw059.
171. Stebbing J, Atkins M, Nelson M, Rajpopat S, Newsom-Davis T, Gazzard B,et al. Hepatitis B reactivation during combination chemotherapy for AIDSrelated lymphoma is uncommon and does not adversely affect outcome. Blood.2004;103:2431–2.
172. Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol. 2002 Jan;81(1):48-9. doi: 10.1007/s00277-001-0393-8. Epub 2001 Dec 11. PMID: 11807636.
173. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br JHaematol. 2007;136:699–712.
174. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol.2011;22:1170–80.
175. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLOS ONE. 2013;8:e68152.
176. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respect al tratamiento antirretroviral en adultos infecta- dos por el virus dela inmunodeficiencia humana. Available from: http://gesida-seimc.org/wp-content/uploads/2017/02/gesida-guiasclinicas-2017-TAR.pdf
177. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.
178. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAgpositive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95.
179. Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, et al. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkittlymphoma is safe when used with concurrent combination antiretroviral therapy.AIDS. 2015;29:903–10.
180. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood.2004;104:2943–6.
181. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooledanalysis of 1546 patients. Blood. 2013;122:3251–62.
182.Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12:905–12.
183.Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIVinfected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519–27.
184. Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon P, et al. The role of tenofovir alafenamide in future HIV management. HIV Med. 2016;17 Suppl. 2:4–16.
185. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood.2001;97:2998–3003.
186. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol. 2001;19:697–704.
187. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growthfactors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.
188. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant.2009;15:1143–238.
189. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patientswith cancer: 2010 update by the Infectious Diseases Society of America. ClinInfect Dis. 2011;52:e56–93.
190. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.
191.Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised Study Group, Nguyen-Van-Tam JS.Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250–9.
192. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18
193. Mondi A, Lorenzini P, Castilletti C, .:INMI Recovery study group. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021 Apr;105:532-539. doi: 10.1016/j.ijid.2021.02.117. Epub 2021 Mar 3. PMID: 33676001; PMCID: PMC7927669.
194. Buske C, Dreyling M, Alvarez-Larrán A, et al.: Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022 Apr;7(2):100403. doi: 10.1016/j.esmoop.2022.100403. Epub 2022 Jan 28.
2. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-1420. PMid:9028965
3. Bibas M. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Prognostic Factors, and Special Populations. Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024007. doi: 10.4084/MJHID.2024.007. PMID: 38223486; PMCID: PMC10786126.
4. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. PMID: 35732829; PMCID: PMC9214472.
5. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851. PMID: 35653592; PMCID: PMC9479027.
6. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 9;125(15):2323-30. doi: 10.1182/blood-2014-10-567479. Epub 2015 Jan 30. PMID: 25636338.
7. Bibas M, Castillo JJ. Current knowledge on HIVassociated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064.
8 .Castillo JJ, Furman M, Beltrán BE,et al.: Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 1;118(21):5270-7. doi: 10.1002/cncr.27551. Epub 2012 Apr 17. PMID: 22510767.
9. Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Survival analysis in treated plasmablastic
lymphoma patients: a population-based study. Am J Hematol. Nov 2020;95(11):1344-1351.
doi:10.1002/ajh.25955).
10. Alec R. Hansen , Victoria A. Vardell , Lindsey A. Fitzgerald , Epidemiologic characteristics, treatment patterns, and survival analysis of Plasmablastic Lymphoma in the US: A SEER and NCDB analysis., Clinical Lymphoma, Myeloma and Leukemia (2023), doi: https://doi.org/10.1016/j.clml.2023.12.014)
11 Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008 Oct;83(10):804-9. doi: 10.1002/ajh.21250. PMID: 18756521.
12. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293-9. doi: 10.1634/theoncologist.2009-0304. Epub 2010 Feb 18. PMID: 20167839; PMCID: PMC3227958.
13. Ibrahim IF, Shapiro GA, Naina HVK. Treatment of HIV-associated plasmablastic lymphoma: a single-center experience with 25 patients. J Clin Oncol 2014; 32(15Suppl):8583.
14 Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, Hu S, Yin CC, Miranda RN, Medeiros LJ, Khoury JD. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015 Jun 10;8:65. doi: 10.1186/s13045-015-0163-z. PMID: 26055271; PMCID: PMC4472407.
15 .Pinnix CC, Shah JJ, Chuang H, et al. Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review. Clin Lymphoma Myeloma Leuk 2016; 16:122-8.
16 .Rudresha AH, Lakshmaiah KC, Agarwal A, et al. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India. South Asian J Cancer 2017; 6:69-71.
17. Focà E, Cavaglià G, Rusconi S, et al. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Med 2018, Online ahead of print
18. Al Tabaa Y, Tchernonog E, Faurie P, et al. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in plasmablastic lymphoma. Eur J Nucl Med Mol Imaging 2018; 45:1705-9.
19. Zuze T, Painschab MS, Seguin R, et al. Plasmablastic lymphoma in Malawi. Infect Agent Cancer 2018; 13:22.
20. Rodrigues-Fernandes CI, de Souza LL, Dos Santos-Costa SF, et al. Clinicopathological analysis of oral plasmablastic lymphoma: a systematic review. J Oral Pathol Med 2018; 47:915-22.
21. Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. PMID: 37832030.
22. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. NCCN 2024;Version 1..2024- 18 January 2024
23. Robak P, Robak T. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9. PMID: 30993606; PMCID: PMC6544598.
24. Leonard JP, Kolibaba K, Reeves JA, et al. Randomized phase 2 openlabel study of R-CHOP ± bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the Pyramid trial (NCT00931918). Blood. 2015;126(23):811. 44.
25. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–953.
26. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20. PMID: 19380866; PMCID: PMC2699229.
27. Jambusaria A, Shafer D, Wu H, Al-Saleem T, Perlis C. Cutaneous plasmablastic lymphoma. J Am Acad Dermatol. 2008 Apr;58(4):676-8. doi: 10.1016/j.jaad.2007.08.009. PMID: 18342714.
28. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009 Jun;82(6):490-2. doi: 10.1111/j.1600-0609.2009.01235.x. Epub 2009 Feb 5. PMID: 19220417.
29.Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010 Dec 1;28(34):e704-8. doi: 10.1200/JCO.2010.30.0038. Epub 2010 Sep 7. PMID: 20823416.
30. Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):E43-6. doi: 10.3816/CLML.2010.n.074. PMID: 21856550.
31. Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013 Sep;31(3):164-6. doi: 10.1002/hon.2024. Epub 2012 Aug 17. PMID: 22899491.
32. Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, Safah H. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36(5):287-91. doi: 10.1159/000350325. Epub 2013 Apr 5. PMID: 23689224.
33. Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e145-50. doi: 10.1016/j.clml.2014.03.002. Epub 2014 Jun 11. PMID: 25225082.
34. Cencini E, Fabbri A, Guerrini S, Mazzei MA, Rossi V, Bocchia M. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016 Jun;96(6):650-654. doi: 10.1111/ejh.12732. Epub 2016 Jan 19. PMID: 26715026.
35.Hirosawa M, Morimoto H, Shibuya R, Shimajiri S, Tsukada J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res. 2015 Nov 4;3:28. doi: 10.1186/s40364-015-0053-0. PMID: 26543559; PMCID: PMC4634743.
36. Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352–355
37. Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, et al. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma. 2016;57(2):463–466.
38. Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, Grigoriadis G. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016 Mar;95(4):667-8. doi: 10.1007/s00277-016-2601-6. Epub 2016 Jan 23. PMID: 26801792.
39. Arora N, Gupta A, Sadeghi N. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. BMJ Case Rep. 2017 Oct 9;2017:bcr2017222063. doi: 10.1136/bcr-2017-222063. PMID: 28993364; PMCID: PMC5652596.
40. Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62(September):12–16
41. Dittus C, Grover N, Ellsworth S, Tan X, Park SI. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma. 2018 Sep;59(9):2121-2127. doi: 10.1080/10428194.2017.1416365. Epub 2018 Jan 5. PMID: 29303024.
42. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. PMID: 29527667.
43. Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, Sawayama Y, Hata T, Ohshima K, Miyazaki Y. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma. Oncol Res Treat. 2020;43(3):112-116. doi: 10.1159/000504608. Epub 2019 Dec 16. PMID: 31842017.
44. Umeanaeto O, Gamboa J, Diaz J, Hakim MN, Corral J, Philipovskiy A, Gaur S. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. Anticancer Res. 2019 Sep;39(9):5003-5007. doi: 10.21873/anticanres.13690. PMID: 31519607.
45. Cai J, Qiu L, Ma L, Zhang N, Fan FY. Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma. Front Med (Lausanne). 2021 Dec 3;8:749863. doi: 10.3389/fmed.2021.749863. PMID: 34926499; PMCID: PMC8677941.
46. Sabry W, Wu Y, Kodad SG. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach. Curr Oncol. 2022 Jul 18;29(7):5042-5053. doi: 10.3390/curroncol29070399. PMID: 35877259; PMCID: PMC9323819.
47. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 1;33(25):2803-11. doi: 10.1200/JCO.2014.59.5363. Epub 2015 Jul 20. PMID: 26195701; PMCID: PMC5320950.
48. Carras, S.; Regny, C.; Peoc’h, M.; Gervasoni, J.; Gressin, R.; Cahn, J.Y.; Molina, L. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric nonhuman immunodeficiency virus-associated plasmablastic lymphoma. Leuk. Lymphoma 2015, 56, 2986–2988. [CrossRef] [PubMed]
49. Yanamandra, U.; Sahu, K.K.; Jain, N.; Prakash, G.; Saikia, U.; Malhotra, P. Plasmablastic lymphoma: Successful management with CHOP and lenalidomide in resource constraint settings. Ann. Hematol. 2016, 95, 1715–1717.
50. Schmit J.M.; Delaune, J.; Norkin, M.; Grosbach, A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol. Res. Treat. 2017, 40, 46–48.
51. Marrero, W.D.; Cruz-Chacón, A.; Castillo, C.; Cabanillas, F. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma. Clin. Lymphoma Myeloma Leuk. 2018, 18, e275–e277.
52..Cheng, L.; Song, Q.; Liu, M.; Wang, Y.; Yi, H.; Qian, Y.; Xu, P.; Cheng, S.; Wang, C.; Wang, L.; et al. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient with Tislelizumab and Lenalidomide. Front. Immunol. 2021, 12, 702593.
53. Lee M, Martin BA, Abdulhaq H. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature. Case Rep Hematol. 2022 Jun 27;2022:8331766. doi: 10.1155/2022/8331766. PMID: 35795542; PMCID: PMC9252825.
54.Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017 Dec;52(4):243-253. doi: 10.5045/br.2017.52.4.243. Epub 2017 Dec 26. PMID: 29333400; PMCID: PMC5762734.
55.Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018 Aug 6;11:4583-4590. doi: 10.2147/OTT.S141053. PMID: 30122950; PMCID: PMC6084082.
56. Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013 Apr 20;31(12):e197-9. doi: 10.1200/JCO.2012.46.9593. Epub 2013 Mar 18. PMID: 23509308.
57. Luo B, Huang L, Gu Y, et al. Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol 2018; 11: 5547–60.
58. Culjkovic-Kraljacic B, Fernando TM, Marullo R, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood 2016; 127: 858–68.
59. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 2017; 129: 3175–83.
60.Laín S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res 1999; 253: 315–24
61.Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727–38
62.Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs 2019; 29: 15–21.
63.Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li RJ, Ma L, et al. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Oncologist. 2021;26(10):879-86.
64.Podar K, Shah J, Chari A, Richardson PG, Jagannath S. Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother. 2020;21(4):399-408
65.Yuhua F, Renjun B, Yonghua Y, Zhang T, Chen L. Selinexor in the Treatment of a Patient with Refractory Plasmablastic Lymphoma: A Case Reports. Ann Short Rep Clin Image. 2022; 3(3): 1028.
66. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004 Apr;121(4):482-8. doi: 10.1309/74R4-TB90-BUWH-27JX. PMID: 15080299.
67. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. PMID: 21187443.
68. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24. PMID: 27222480; PMCID: PMC4957162.
69.Morabito F, Damle RN, Deaglio S et al. The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol. Med. 2006; 12(11–12):342–4.
70. Patten PEM, Buggins AGS, Richards J et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008; 111(10):5173–81.
71.Konoplev S, Medeiros LJ, Bueso-Ramos CE et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am. J. Clin. Pathol. 2005;124(3):414–20.
72. Parry-Jones N, Matutes E, Morilla R et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: A study of 60 cases by FISH. Br. J. Haematol. 2007; 137(2):117–124.
73. Keyhani A, Huh YO, Jendiroba D et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk. Res. 2000; 24(2):153–9.
74.Marinov J, Koubek K, Starý J. Immunophenotypic significance of the “lymphoid” CD38 antigenin myeloid blood malignancies. Neoplasma 1993; 40(6):355–8.
75.Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer-cell leukemia revisited:large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18(4):763–70.
76.Wang L, Wang H, Li P et al. CD38 expression predicts poor prognosis and might be a potentialtherapy target in extranodal NK/T cell lymphoma, nasal type. Ann. Hematol. 2015;94(8):1381–8.
77. Hari P, Raj R V, Olteanu H. Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-CellLymphoma. N. Engl. J. Med. 2016; 375(15):1501–1502.
78. Bride KL, Vincent TL, Im S-Y et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018; 131(9):995–999.
79. Overdijk MB, Verploegen S, Bögels M et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015; 7(2):311–21.
80. Chikeka I, Grossman M, Deng C, Jacob AT, Husain S. Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. JAAD Case Rep. 2020 Feb 12;6(3):161-165. doi: 10.1016/j.jdcr.2019.11.007. PMID: 32083160; PMCID: PMC7019043.
81. Marvyin K, Tjønnfjord EB, Breland UM, Tjønnfjord GE. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. BMJ Case Rep. 2020 Sep 29;13(9):e235816. doi: 10.1136/bcr-2020-235816. PMID: 32994268; PMCID: PMC7526319.
82. Roché P, Venton G, Berda-Haddad Y, Fritz S, Ivanov V, Mercier C, Colle J, Tichadou A, Fanciullino R, Lepidi H, Costello R, Farnault L. Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?-Potential therapeutic applications. Eur J Haematol. 2021 Apr;106(4):589-592. doi: 10.1111/ejh.13584. Epub 2021 Feb 2. PMID: 33469987.
83. Ricker E, Yun Kyoung Ryu, Jennifer E. Amengual, Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma, Blood,Volume 138, Supplement 1,2021,Page 4573
84. Ramadas P, Williams M, Duggan DB. Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder. Case Rep Hematol. 2021 Sep 27;2021:4354941. doi: 10.1155/2021/4354941. PMID: 34616575; PMCID: PMC8490046.
85. Kathrotiya M, Radhakrishnan VS, Bhave SJ, Kumar J, Roychowdhury M, Arun I, Das J, Chandy M, Nair R. Relapsed plasmablastic lymphoma in a HIV-negative patient: Pushing the envelope. Clin Case Rep. 2020 Dec 20;9(2):873-877. doi: 10.1002/ccr3.3673. PMID: 33598263; PMCID: PMC7869339.
86. Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J Clin Med. 2022 Aug 22;11(16):4928. doi: 10.3390/jcm11164928. PMID: 36013165; PMCID: PMC9409851.
87. Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023 Feb 15;30(2):2322-2347. doi: 10.3390/curroncol30020179. PMID: 36826140; PMCID: PMC9954856.
88. Pinto MP, Thorneloe NS, Brown MR, Stalons ML, Stoll KE, Holmes AR, Pathan M, Gonzales PA. The devolution of a mature plasma cell dyscrasia into a fatal plasmablastic lymphoma. J Case Rep Images Oncology 2023;9(2):7–14.
89. Dornan D, Bennett F, Chen Y et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkinlymphoma. Blood 114:2721–2729
90. Deeks ED (2019) Polatuzumab vedotin: first global approval. Drugs 79:1467–1475.
91. Palanca-Wessels MCA, Czuczman M, Salles G et al (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
92. Sehn L, Herrera A, Flowers C et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155–165
93. Northend M, Wilson W, Osborne W. et al.: Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. PMID: 35020818; PMCID: PMC9092410.
94. Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017, 8, 561.
95. Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11, 3887–3895.
96. Ishida, Y. PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells 2020, 9, 1376.
97. Jalali, S.; Price-Troska, T.; Bothun, C.; Villasboas, J.; Kim, H.J.; Yang, Z.Z.; Novak, A.J.; Dong, H.; Ansell, S.M. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019, 9, 22.
98. Xu-Monette, Z.Y.; Zhou, J.; Young, K.H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 2018, 131, 68–83.
99. Garcia-Lacarte, M.; Grijalba, S.C.; Melchor, J.; Arnaiz-Leche, A.; Roa, S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers 2021, 13, 4683.
100. Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2, 261–268.
101. Xia, Y.; Medeiros, L.J.; Young, K.H. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016, 30, 189–200.
102. Bardhan, K.; Anagnostou, T.; Boussiotis, V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front.Immunol. 2016, 7, 550.
103. Azuma, T.; Yao, S.; Zhu, G.; Flies, A.S.; Flies, S.J.; Chen, L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008,111, 3635–3643.
104. Zhang, J.P.; Song, Z.; Wang, H.B.; Lang, L.; Yang, Y.Z.; Xiao, W.; Webster, D.E.; Wei, W.; Barta, S.K.; Kadin, M.E.; et al. A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening. Blood 2019, 134,171–185.
105. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.;Gettinger, S.N.; et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014,515, 563–567.
106. Xie, W.; Medeiros, L.J.; Li, S.; Yin, C.C.; Khoury, J.D.; Xu, J. PD-1/PD-L1 Pathway and Its Blockade in Patients with ClassicHodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr. Hematol. Malig. Rep. 2020, 15, 372–381.
107. Ansell, S.M. PD-1 Blockade in Classic Hodgkin Lymphoma. JCO Oncol. Pract. 2021, 17, 72–73. [CrossRef]
108. Chen, B.J.; Chapuy, B.; Ouyang, J.; Sun, H.H.; Roemer, M.G.; Xu, M.L.; Yu, H.; Fletcher, C.D.; Freeman, G.J.; Shipp, M.A.; et al.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res.2013, 19, 3462–3473.
109.Kiyasu, J.; Miyoshi, H.; Hirata, A.; Arakawa, F.; Ichikawa, A.; Niino, D.; Sugita, Y.; Yufu, Y.; Choi, I.; Abe, Y.; et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood2015, 126, 2193–2201
110. Granai M, Mundo L, Akarca AU, Siciliano MC, Rizvi H, Mancini V, Onyango N, Nyagol J, Abinya NO, Maha I, Margielewska S, Wi W, Bibas M, Piccaluga PP, Quintanilla-Martinez L, Fend F, Lazzi S, Leoncini L, Marafioti T. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infect Agent Cancer. 2020 May 6;15:28. doi: 10.1186/s13027-020-00292-w. Erratum in: Infect Agent Cancer. 2020 Jun 10;15:39. PMID: 32391073; PMCID: PMC7201729.
111. Xing, W.; Dresser, K.; Zhang, R.; Evens, A.M.; Yu, H.; Woda, B.A.; Chen, B.J. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications. Oncotarget 2016, 7, 59976–59986.
112. Laurent C, Fabiani B, Do C, Tchernonog E, Cartron G, Gravelle P, Amara N, Malot S, Palisoc MM, Copie-Bergman C, Glehen AT, Copin MC, Brousset P, Pittaluga S, Jaffe ES, Coppo P. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016 Aug;101(8):976-84. doi: 10.3324/haematol.2016.141978. Epub 2016 May 12. PMID: 27175027; PMCID: PMC4967577.
113. Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C. EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology. 2018 Jul 30;7(10):e1486950. doi: 10.1080/2162402X.2018.1486950. PMID: 30288350; PMCID: PMC6169584.
114. Damlaj M., Alzayed M., Alahmari B., Alhejazi A., Alaskar A., Alzahrani M. Therapeutic potential of checkpoint inhibitors in refractory plasmablastic lymphoma. Clinical Lymphoma Myeloma and Leukemia . 2019;19(10):e559–e563. doi: 10.1016/j.clml.2019.06.008. [PubMed] [CrossRef] [Google Scholar]
115.Cheng L., Song Q., Liu M., et al. Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide. Frontiers in Immunology . 2021;12 doi: 10.3389/fimmu.2021.702593.702593
116. Castillo JJ, Lamacchia J, Silver J, Flynn CA, Sarosiek S. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 Oct 1;96(10):E390-E392. doi: 10.1002/ajh.26291. Epub 2021 Aug 2. PMID: 34260089.
117. Schuster, S.J. , Svoboda, J. , Chong, E.A. , Nasta, S.D. , Mato, A.R. , Anak, O. , Brogdon, J.L. , Pruteanu‐Malinici, I. , Bhoj, V. , Landsburg, D. , Wasik, M. , Levine, B.L. , Lacey, S.F. , Melenhorst, J.J. , Porter, D.L. & June, C.H. (2017) Chimeric antigen receptor T cells in refractory B‐cell lymphomas. The New England Journal of Medicine, 377, 2545–2554.
118. Abramson, J.S. & Chen, Y.B. (2017) More on anti‐CD19 CAR T cells in CNS diffuse large‐B‐cell lymphoma. The New England Journal of Medicine, 377, 2102.
119. Testa U, Leone G, Pelosi E, Castelli G, Hohaus S. CAR-T Cell Therapy in Large B Cell Lymphoma. Mediterr J Hematol Infect Dis. 2023 Nov 1;15(1):e2023066. doi: 10.4084/MJHID.2023.066. PMID: 38028399; PMCID: PMC10631715.
120 .Parker C, Liu FF, Deger KA, Franco-Villalobos C, Proskorovsky I, Keating SJ, Sorensen S. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Adv Ther. 2023 May;40(5):2355-2374. doi: 10.1007/s12325-023-02444-x. Epub 2023 Mar 22. PMID: 36947328; PMCID: PMC10129927.
121 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. PMID: 34478487; PMCID: PMC8945634.
122.Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwartz E, Jakovach M, Martinez-Prieto M, Agarwal A, Degtyarev E, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2022; 6: 2536-2542.
123.Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022, 386(7): 629-639.
124. Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Med 2022; 28: 2145-
125. Raychaudhuri R, Qualtieri J, Garfall AL. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. Am J Hematol. 2020 Jan;95(1):E28-E30. doi: 10.1002/ajh.25682. Epub 2019 Nov 25. PMID: 31725923.
126. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014 Dec;20(12):1877-84. https://doi.org/10.1016/j.bbmt.2014.06.009 PMid:24946718
127. Cattaneo C, Finel H, McQuaker G, Vandenberghe E, Rossi G, Dreger P. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant. 2015 Jun;21(6):1146-7.
128. Balsalobre P, Diez-Martin J, Re A, et al. Autologous stem cell transplantation in patients with HIV related lymphoma. J Clin Oncol. 2009; 27:2192-2198
129. Re A, Michieli M, Allione B, et al. Early consolidation with high dose therapy and autologous stem cell transplantation in HIV-associated Non Hodgkin Lymphoma at high risk (aa-IPI 2-3), an interim report of a multicenter phase II trial. Blood. 2012;120. Abstract 731.
130. Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among HIVpositive patients: results of a single centre’s experience. Leuk Lymphoma. 2014 Apr 9 [Epub ahead of print].
131. Broccoli A, Nanni L, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer. 2018 Jun 8;18(1):645. doi: 10.1186/s12885-018-4561-9. PMID: 29879938; PMCID: PMC5992724.
132. M. Hamadani, S.M. Devine.Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood,114 (2009), pp. 2564-2566
133. Rong C, Sheng L, Wu A, Sun Y, Ouyang G. Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24498. doi: 10.1097/MD.0000000000024498. PMID: 33607779; PMCID: PMC7899902
134. Illidge T, Specht L, Yahalom J, et al. Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 2014;89(1):49–58
136. Ng AK, Yahalom J, Goda JS, et al. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 2018;100(3):652–69.
137. Shi Z, Das S, Okwan-Duodu D, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):569-577. doi:10.1016/j.ijrobp.2013.02.007
138. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170-4176. doi:10.1200/JCO.2009.27.3441
139. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032-3038. doi:10.1200/JCO.2004.06.088
140. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21-26. doi:10.1056/NEJM199807023390104
141. Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112-1118. doi:10.1200/JCO.2013.51.4505
142. Pfreundschuh M, Murawski N, Ziepert M, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J Clin Oncol. 2018;36(15_suppl):7574-7574. doi:10.1200/JCO.2013.51.4505
143. Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115-4122. doi:10.1200/JCO.2012.48.0467
144. Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-669. doi:10.1016/j.ijrobp.2017.12.005
145. Wright CM, Koroulakis AI, Baron JA, et al. Palliative radiotherapy for diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(10):650-658. doi:10.1016/j.clml.2021.05.007
146. Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol Rep. 2015 Apr;33(4):1615-20. doi: 10.3892/or.2015.3808. Epub 2015 Feb 17. PMID: 25695332; PMCID: PMC4358079.
147. Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fabiani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017 Apr 1;28(4):843-848. doi: 10.1093/annonc/mdw684. PMID: 28031174.
148. Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 Feb;98(2):300-308. doi: 10.1002/ajh.26784. Epub 2023 Jan 1. PMID: 36588409; PMCID: PMC10107934.
149. Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516.
150. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis—a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15(8):451-457.
151. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926.
152. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-3156.
153.Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):578-586.
154.Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br JHaematol. 2017;176(2):210-221.
155. Hu S, Song Y, Li Y, et al. Primary breast diffuse large B cell lymphoma in the rituximab era: outcomes of a multicenter retrospective study by the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society (LLC-CGOS). Paper presented at: 58th Annual Meeting of the American Society of Hematology; 3-6 December 2016; San Diego, CA.
156. McKay P, Wilson MR, Chaganti S, et al; British Society of Haematology. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2020;190(5):708-714.
157. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer.2017;75(April):195-203.
158. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.Blood. 2016;127(18):2182-2188
159.Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2014;99(7):1228-1235.
160. Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica.2020;105(7):1914-1924.
161.Eyre TA, Kirkwood AA, Wolf J, et al. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br J Haematol. 2019;187(2):185-194
162.Barta SK, Joshi J, Mounier N, et al. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol 2016;173:857-66.
163. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al.Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521–9.
164. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430–8.
165. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol. 2001;112:909–15.
166. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91:155–63.
167.Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, et al Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect. 2014;20:O672–9.
168. Gonzalez-Garcia JJ, Mahillo B, Hernandez S, Pacheco R, Diz S, Garcia P, et al. [Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients.The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. Enferm Infecc Microbiol Clin. 2005;23:340–8.
169. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS.2005;19:593–601.
170. Berenguer J, Rivero A, Jarrin I, Nunez MJ, Vivancos MJ, Crespo M, et al. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics. Open Forum Infect Dis. 2016;3:ofw059.
171. Stebbing J, Atkins M, Nelson M, Rajpopat S, Newsom-Davis T, Gazzard B,et al. Hepatitis B reactivation during combination chemotherapy for AIDSrelated lymphoma is uncommon and does not adversely affect outcome. Blood.2004;103:2431–2.
172. Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol. 2002 Jan;81(1):48-9. doi: 10.1007/s00277-001-0393-8. Epub 2001 Dec 11. PMID: 11807636.
173. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br JHaematol. 2007;136:699–712.
174. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol.2011;22:1170–80.
175. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLOS ONE. 2013;8:e68152.
176. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respect al tratamiento antirretroviral en adultos infecta- dos por el virus dela inmunodeficiencia humana. Available from: http://gesida-seimc.org/wp-content/uploads/2017/02/gesida-guiasclinicas-2017-TAR.pdf
177. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.
178. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAgpositive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95.
179. Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, et al. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkittlymphoma is safe when used with concurrent combination antiretroviral therapy.AIDS. 2015;29:903–10.
180. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood.2004;104:2943–6.
181. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooledanalysis of 1546 patients. Blood. 2013;122:3251–62.
182.Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12:905–12.
183.Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIVinfected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519–27.
184. Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon P, et al. The role of tenofovir alafenamide in future HIV management. HIV Med. 2016;17 Suppl. 2:4–16.
185. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood.2001;97:2998–3003.
186. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol. 2001;19:697–704.
187. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growthfactors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.
188. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant.2009;15:1143–238.
189. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patientswith cancer: 2010 update by the Infectious Diseases Society of America. ClinInfect Dis. 2011;52:e56–93.
190. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.
191.Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised Study Group, Nguyen-Van-Tam JS.Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250–9.
192. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18
193. Mondi A, Lorenzini P, Castilletti C, .:INMI Recovery study group. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021 Apr;105:532-539. doi: 10.1016/j.ijid.2021.02.117. Epub 2021 Mar 3. PMID: 33676001; PMCID: PMC7927669.
194. Buske C, Dreyling M, Alvarez-Larrán A, et al.: Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022 Apr;7(2):100403. doi: 10.1016/j.esmoop.2022.100403. Epub 2022 Jan 28.
Article Sidebar
Published
Feb 29, 2024
Article Details
How to Cite
Bibas, M. (2024) “The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY”, Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024015. doi: 10.4084/MJHID.2024.015.
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.